Evidence map›Paper›PMID 33788346›Full record

ArticleCancer science2021

VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.

Yingxia Ning, Zhaoyang Zeng, Yuao Deng, Weifeng Feng, Lun Huang, Huiling Liu, Jiazhi Lin, Chen Zhang, Yue Fan, Longyang Liu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Correction.Cancer science · 2021
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Yingxia NingDepartment of Gynecology, the Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
Zhaoyang ZengDepartment of Gynecology, the Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
Yuao DengDepartment of Gynecology and Obstetrics, Shenzhen People's Hospital, Shenzhen, China.
Weifeng FengThe First Affiliated Hospital of Jinan University, Guangzhou, China.
Lun HuangDepartment of Gynaecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Huiling LiuDepartment of Gynaecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jiazhi LinDepartment of Gynaecology and Obstetrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Chen ZhangDepartment of Clinical Pharmacy, Guangzhou First People's Hospital, Guangzhou, China.
Yue FanCancer Research Institute, Southern Medical University, Guangzhou, China.
Longyang LiuCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-1014-3625
First Affiliated Hospital of Guangzhou Medical University · CNTCM-Intigrated Cancer Center of Southern Medical University · CNFirst Affiliated Hospital of Jinan University · CNGuangzhou First People's Hospital · CNShenZhen People’s Hospital · CNSouthern Medical University · CN

Funding

Natural Science Foundation of Guangdong Province 2018A0303130180
6 · The paper itself

Abstract

The pathogenesis and cisplatin chemoresistance of ovarian cancer (OC) are still unclear. Vacuolar protein sorting-associated 33B (VPS33B) has not been reported in OC to date. In this study, immunohistochemistry was used to detect VPS33B protein expression between OC and ovarian tissues. MTT, EdU, colony formation, cell cycle, in vivo tumorigenesis, western blot, ChIP, EMSA, co-immunoprecipitation (CoIP), qRT-PCR, and microconfocal microscopy were used to explore the function and molecular mechanisms of VPS33B in OC cells. The results of the present study demonstrated that VPS33B protein expression was obviously reduced in OC compared with that in ovarian tissues. Overexpressed VPS33B suppressed cell cycle transition, cell growth, and chemoresistance to cisplatin in vitro and in vivo. Analysis of the mechanism indicated that overexpressed VPS33B regulated the epidermal growth factor receptor (EGFR)/PI3K/AKT/c-Myc/p53/miR-133a-3p feedback loop and reduced the expression of the cell cycle factor CDK4. Nasopharyngeal epithelium-specific protein 1 (NESG1) as a tumor suppressor not only interacted with VPS33B, but was also induced by VPS33B by the attenuation of PI3K/AKT/c-Jun-mediated transcription inhibition. Overexpressed NESG1 further suppressed cell growth by mediating VPS33B-modulated signals in VPS33B-overexpressing OC cells. Finally, NESG1 induced VPS33B expression by reducing the inhibition of PI3K/AKT/c-Jun-mediated transcription. Our study is the first to demonstrate that VPS33B serves as a tumor suppressor, and VPS33B can interact with NESG1 to suppress cell growth and promote cisplatin sensitivity by regulating the EGFR/PI3K/AKT/c-Myc/p53/miR-133a-3p feedback loop in OC cells.

Indexed as

AnimalsAntineoplastic AgentsCell CycleCell Line, TumorCell MovementCell ProliferationCisplatinCyclin-Dependent Kinase 4Cytoskeletal ProteinsDrug Resistance, NeoplasmErbB ReceptorsFemaleGenes, Tumor SuppressorHumansMiceMice, Inbred BALB CAntineoplastic AgentsCDK4 protein, humanCFAP45 protein, humanCisplatinCyclin-Dependent Kinase 4Cytoskeletal ProteinsErbB ReceptorsMicroRNAsMIRN133 microRNA, humanMYC protein, humanNeoplasm ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycTumor Suppressor Protein p53Vesicular Transport ProteinsVPS33B protein, humanAKTc-MycEGFRmiR-133a-3pNESG1PI3KVPS33B

Identifiers

PMID33788346
PMCPMC8088924
OpenAlexW3149713501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.